The short version of GHRH analog fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-01-05 and is reviewed periodically as new material appears.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
== N-Glycosidic bonds in DNA == DNA molecules contain 5-membered carbon rings called deoxyriboses that are directly attached to two phosphate groups and a nucleobase that contains amino groups. The nitrogen atoms from the amino group in the nucleotides are covalently linked to the anomeric carbon of the ribose sugar structure through an N-glycosidic bond. Occasionally, the nucleobases attached to the ribose undergo deamination, alkylation, or oxidation which results in cytotoxic lesions along the DNA backbone. These modifications severely threaten the cohesiveness of the DNA molecule, leading to the development of diseases such as cancer. DNA glycosylases are enzymes that catalyze the hydrolysis the N-glycosidic bond to free the damaged or modified nucleobase from the DNA, by cleaving the carbon-nitrogen glycosidic bond at the 2' carbon, subsequently initiating the base excision repair (BER) pathway. Monofunctional glycosylases catalyze the hydrolysis of the N-glycosidic bond via either a stepwise, SN1 like mechanism, or a concerted, SN2 like mechanism. The stepwise function, the nucleobase acts as a leaving group before the anomeric carbon gets attacked by the water molecule, producing a short-lived unstable oxacarbenium ion intermediate. This intermediate rapidly reacts with the nearby water molecule to substitute the N-glycosidic bond of the ribose and the nucleobase with an O-glycosidic bond with a hydroxy group. The concerted mechanism, the water acts as a nucleophile and attacks at the anomeric carbon before the nucelobase gets to act like a leaving group.
2 K + H2 → 2 KH It is a white, pyrophoric solid that finds some use as a base. All of the halides salts are well known: potassium fluoride (KF), potassium chloride (KCl), potassium bromide (KBr), and potassium iodide (KI). Four oxides of potassium are well studied: potassium oxide (K2O), potassium peroxide (K2O2), potassium superoxide (KO2) and potassium ozonide (KO3). These species all hydrolyze (react with water) to give potassium hydroxide. Similarly an extensive array of sulfides, selenides, and tellurides are well characterized. Although such simple salts are typically white and diamagnetic, KO2 is something of an exception, being deep yellow and paramagnetic.
==== G protein-linked receptors ==== The G protein-linked signaling cascade can significantly amplify the signal of a particular neurotransmitter to produce hundreds to thousands of second messengers in a cell. The mechanism of action by which G protein-linked receptors cause a signaling cascade is as follows:
=== Beyond Raw === GNC is a company that offers creatine supplements in both pill and powder forms through its GNC AMP® and Beyond Raw® Chemistry Labs product lines. Their products have been scientifically supported and clinically tested, such as the GNC AMP® Creatine HCl 189™. In collaboration with The Hershey Company, products like Beyond Raw® LIT™ JOLLY RANCHER Grape pre-workout powder and on the-go have been produced which come in flavours like watermelon, green apple, and blue raspberry. Each pre-workout supplement contains clinically dosed ingredients, such as L-Citrulline, CarnoSyn betaalanine, micronized creatine, caffeine, and Nitrosigine. Other supplements like Burn MF Metabolic Activator Powder, Capsules, Sticks, and Drink belong to the Beyond Raw brand. Additionally, the text mentions that a new flavor, JOLLY RANCHER Grape, has been launched after the release of another supplement called Beyond Raw Concept X in May 2022. However, in a settlement with the Department of Justice, GNC, the largest retailer of supplements in the country, has agreed to pay $2.25 million. This settlement comes as part of a larger effort by the federal government to crack down on supplements that contain undisclosed drug ingredients, harmful compounds, or inaccurate ingredient labeling. As part of the settlement, GNC has committed to improving its product screening process and removing any supplements containing illegal or unsafe ingredients. In addition, the company will maintain a list of products that have been deemed safe for sale.
Sources: en.wikipedia.org
== Regulation == G6PD converts G6P into 6-phosphoglucono-δ-lactone and is the rate-limiting enzyme of the pentose phosphate pathway. Thus, regulation of G6PD has downstream consequences for the activity of the rest of the pentose phosphate pathway. Glucose-6-phosphate dehydrogenase is stimulated by its substrate G6P. The usual ratio of NADPH/NADP+ in the cytosol of tissues engaged in biosyntheses is about 100/1. Increased utilization of NADPH for fatty acid biosynthesis will dramatically increase the level of NADP+, thus stimulating G6PD to produce more NADPH. Yeast G6PD is inhibited by long chain fatty acids according to two older publications and might be product inhibition in fatty acid synthesis which requires NADPH. G6PD is negatively regulated by acetylation on lysine 403 (Lys403), an evolutionarily conserved residue. The K403 acetylated G6PD is incapable of forming active dimers and displays a complete loss of activity. Mechanistically, acetylating Lys403 sterically hinders the NADP+ from entering the NADP+ structural site, which reduces the stability of the enzyme. Cells sense extracellular oxidative stimuli to decrease G6PD acetylation in a SIRT2-dependent manner. The SIRT2-mediated deacetylation and activation of G6PD stimulates pentose phosphate pathway to supply cytosolic NADPH to counteract oxidative damage and protect mouse erythrocytes. Regulation can also occur through genetic pathways. The isoform, G6PDH, is regulated by transcription and posttranscription factors.
Highly popular Fast Forward holds influence over the other foster children, introducing them to drugs and pressuring them to give him money. Demon's mom, now pregnant, overdoses on oxyContin for the second time and dies. Demon returns for the funeral and spends Christmas with the Peggots, joining them on another trip to Knoxville. June has decided to move back to Lee County due to her colleagues in Knoxville demeaning her for being a 'redneck'. Demon begs the Peggots to adopt him, but they apologize and tell him their old age makes it impossible. A heartbroken Demon leaves Creaky Farms and is sent to stay with another neglectful foster family, the McCobbs, where he largely goes hungry and is made to feel like a financial burden. He is able to save some money by working for Mr. Ghali, a Dalit immigrant from India, who runs a garbage disposal operation (and implied meth lab) out of a gas station. Demon, now in fifth grade, remains neglected at home and is mocked at school for his unkempt appearance and bad smell. The McCobbs are forced to move due to financial issues. Demon runs away to avoid another foster placement. Neglected and hungry, Demon decides to hitchhike to Murder Valley, Tennessee, to find his paternal grandmother. He finds his grandmother Betsy Woodall, a hardy old woman who lives with her disabled brother Dick. Betsy contacts Coach Winfield, the coach of the Lee High Generals, who takes Demon in. Demon moves to Coach's mansion where he meets his daughter Agnes (nicknamed Angus after a misunderstanding) and a young man named U-Haul who assists Coach.
== Methods == Scarification is not a precise practice; variables, such as skin type, cut depth, and how the wound is treated while healing, can make the outcome unpredictable compared to other forms of body modification. A method that works on one person may not work on another. The scars tend to spread as they heal, so final designs are usually simple, the details being lost during healing.Some common scarification techniques include: Ink rubbing Tattoo ink (or similar agent) is rubbed into a fresh cut to add color or extra visibility to the scar. Most of the ink remains in the skin as the cut heals. This was how tattoos were initially done before the use of needles to inject ink. Skin removal/skinning Skin removal allows for larger markings than simple cutting. The skin is raised with a hook or edged thorn and removed with a razor blade. This process can take many hours, and often requires repeated removal of scabs for best visibility of the scars. Packing An inert material such as clay or ash is packed into the wound; massive hypertrophic scars are formed during healing as the wound pushes out the substance that had been inserted into the wound. Inflammatory substances can be used to improve keloid formation.
The International Supply Chain Education Alliance (ISCEA) is a certifying body. Founded in 2003 and currently holding over 100,000 members, ISCEA has its World HQ office in Beachwood, OH, USA and regional offices in LATAM, EMEA and APAC. ISCEA is the governing body for the Ptak Prize. Besides Certified Supply Chain Manager (CSCM) certification, ISCEA has developed several professional certification programs that include: Certified Supply Chain Analyst (CSCA), Certified Lean Master (CLM), Certified RFID Supply Chain Manager (RFIDSCM), Certified Demand Driven Planner (CDDP), Certified HealthCare Supply Chain Analyst (CHSCA); and Certified Lean Six Sigma Yellow Belt (CLSSYB), Green Belt (CLSSGB) and Black Belt (CLSSBB).
=== Expansion and acquisition === By 1997, Reddy's made the transition from being an API and bulk drug supplier to regulated markets like the US and the UK, and a branded formulations supplier in unregulated markets like India and Russia, into producing generics, by filing an Abbreviated New Drug Application (ANDA) in the USA. The same year, Reddy's out-licensed a molecule for clinical trials to Novo Nordisk, a Danish pharmaceutical company. It strengthened its Indian manufacturing operations by acquiring American Remedies Ltd. in 1999. This acquisition made Reddy's the third largest pharmaceutical company in India, after Ranbaxy and Glaxo (I) Ltd., with a full spectrum of pharmaceutical products, which included bulk drugs, intermediates, finished dosages, chemical synthesis, diagnostics and biotechnology. Reddy's also started exploiting Para 4 filing as a strategy in bringing new drugs to the market at a faster pace. In 1999 it submitted a Para 4 application for omeprazole, the drug that had been the cornerstone of its success in India. In December 2000, Reddy's had undertaken its first commercial launch of a generic product in the US, and its first product with market exclusivity was launched there in August 2001. The same year, it also became the first non-Japanese pharmaceutical company from the Asia-Pacific region to obtain a New York Stock Exchange listing. In 2001 Reddy's became the first Indian company to launch the generic drug, fluoxetine (a generic version of Eli Lilly and Company’s Prozac) with 180-day market exclusivity in the USA.
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.